Cargando…

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after all...

Descripción completa

Detalles Bibliográficos
Autores principales: Poiré, Xavier, Labopin, Myriam, Maertens, Johan, Yakoub-Agha, Ibrahim, Blaise, Didier, Ifrah, Norbert, Socié, Gérard, Gedde-Dhal, Tobias, Schaap, Nicolaas, Cornelissen, Jan J., Vigouroux, Stéphane, Sanz, Jaime, Michaux, Lucienne, Esteve, Jordi, Mohty, Mohamad, Nagler, Arnon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241968/
https://www.ncbi.nlm.nih.gov/pubmed/28100265
http://dx.doi.org/10.1186/s13045-017-0393-3
_version_ 1782496272248209408
author Poiré, Xavier
Labopin, Myriam
Maertens, Johan
Yakoub-Agha, Ibrahim
Blaise, Didier
Ifrah, Norbert
Socié, Gérard
Gedde-Dhal, Tobias
Schaap, Nicolaas
Cornelissen, Jan J.
Vigouroux, Stéphane
Sanz, Jaime
Michaux, Lucienne
Esteve, Jordi
Mohty, Mohamad
Nagler, Arnon
author_facet Poiré, Xavier
Labopin, Myriam
Maertens, Johan
Yakoub-Agha, Ibrahim
Blaise, Didier
Ifrah, Norbert
Socié, Gérard
Gedde-Dhal, Tobias
Schaap, Nicolaas
Cornelissen, Jan J.
Vigouroux, Stéphane
Sanz, Jaime
Michaux, Lucienne
Esteve, Jordi
Mohty, Mohamad
Nagler, Arnon
author_sort Poiré, Xavier
collection PubMed
description BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after allo-SCT in patients with abn(17p), we retrospectively analysed de novo or secondary AML undergoing SCT between 2000 and 2013 from the EBMT registry. RESULTS: One hundred thirty-nine patients with confirmed abn(17p) have been selected. At the time of transplant, one hundred twenty-five were in first remission (CR1). Median age was 54 years old. Abn(17p) was associated with a monosomal karyotype in 83% of patients, complex karyotype in 91%, monosomy 5 or 5q deletion (-5/5q-) in 55%, monosomy 7 (-7) in 39% and both -5/5q and -7 in 27%. Seventy-three patients (59%) had a reduced-intensity conditioning regimen. The 2-year overall survival (OS) and leukaemia-free survival (LFS) were 28 and 24%, respectively. The 2-year non-relapse mortality (NRM) was 15%, and 2-year relapse incidence (RI) was 61%. The cumulative incidence of grade II to IV acute graft-versus-host disease (GvHD) was 24% and that of chronic GvHD was 21%. In multivariate analysis, the presence of a -5/5q- in addition to abn(17p) was significantly and independently associated with worse OS, LFS and higher RI. Age and donor types did not correlate with outcome. Conditioning intensity was not statistically associated with OS, LFS and NRM when adjusted for patients’ age. CONCLUSIONS: In contrast to the dismal prognosis reported for AML patients harbouring abn(17p) undergoing conventional chemotherapy, allogeneic SCT provides responses in about 25% of those patients transplanted in CR1. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0393-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5241968
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52419682017-01-23 Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) Poiré, Xavier Labopin, Myriam Maertens, Johan Yakoub-Agha, Ibrahim Blaise, Didier Ifrah, Norbert Socié, Gérard Gedde-Dhal, Tobias Schaap, Nicolaas Cornelissen, Jan J. Vigouroux, Stéphane Sanz, Jaime Michaux, Lucienne Esteve, Jordi Mohty, Mohamad Nagler, Arnon J Hematol Oncol Research BACKGROUND: Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. METHODS: To address outcomes after allo-SCT in patients with abn(17p), we retrospectively analysed de novo or secondary AML undergoing SCT between 2000 and 2013 from the EBMT registry. RESULTS: One hundred thirty-nine patients with confirmed abn(17p) have been selected. At the time of transplant, one hundred twenty-five were in first remission (CR1). Median age was 54 years old. Abn(17p) was associated with a monosomal karyotype in 83% of patients, complex karyotype in 91%, monosomy 5 or 5q deletion (-5/5q-) in 55%, monosomy 7 (-7) in 39% and both -5/5q and -7 in 27%. Seventy-three patients (59%) had a reduced-intensity conditioning regimen. The 2-year overall survival (OS) and leukaemia-free survival (LFS) were 28 and 24%, respectively. The 2-year non-relapse mortality (NRM) was 15%, and 2-year relapse incidence (RI) was 61%. The cumulative incidence of grade II to IV acute graft-versus-host disease (GvHD) was 24% and that of chronic GvHD was 21%. In multivariate analysis, the presence of a -5/5q- in addition to abn(17p) was significantly and independently associated with worse OS, LFS and higher RI. Age and donor types did not correlate with outcome. Conditioning intensity was not statistically associated with OS, LFS and NRM when adjusted for patients’ age. CONCLUSIONS: In contrast to the dismal prognosis reported for AML patients harbouring abn(17p) undergoing conventional chemotherapy, allogeneic SCT provides responses in about 25% of those patients transplanted in CR1. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0393-3) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-18 /pmc/articles/PMC5241968/ /pubmed/28100265 http://dx.doi.org/10.1186/s13045-017-0393-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Poiré, Xavier
Labopin, Myriam
Maertens, Johan
Yakoub-Agha, Ibrahim
Blaise, Didier
Ifrah, Norbert
Socié, Gérard
Gedde-Dhal, Tobias
Schaap, Nicolaas
Cornelissen, Jan J.
Vigouroux, Stéphane
Sanz, Jaime
Michaux, Lucienne
Esteve, Jordi
Mohty, Mohamad
Nagler, Arnon
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
title Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
title_full Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
title_fullStr Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
title_full_unstemmed Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
title_short Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
title_sort allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the acute leukemia working party (alwp) of the european society for blood and marrow transplantation (ebmt)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241968/
https://www.ncbi.nlm.nih.gov/pubmed/28100265
http://dx.doi.org/10.1186/s13045-017-0393-3
work_keys_str_mv AT poirexavier allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT labopinmyriam allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT maertensjohan allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT yakoubaghaibrahim allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT blaisedidier allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT ifrahnorbert allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT sociegerard allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT geddedhaltobias allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT schaapnicolaas allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT cornelissenjanj allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT vigourouxstephane allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT sanzjaime allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT michauxlucienne allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT estevejordi allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT mohtymohamad allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt
AT naglerarnon allogeneicstemcelltransplantationinadultpatientswithacutemyeloidleukaemiaand17pabnormalitiesinfirstcompleteremissionastudyfromtheacuteleukemiaworkingpartyalwpoftheeuropeansocietyforbloodandmarrowtransplantationebmt